• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Sirtuins 作为潜在治疗靶点的概述:结构、功能和调节剂。

An overview of Sirtuins as potential therapeutic target: Structure, function and modulators.

机构信息

State Key Laboratory of Biotherapy & Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.

Sichuan Nursing Vocational College, Chengdu 610100, China.

出版信息

Eur J Med Chem. 2019 Jan 1;161:48-77. doi: 10.1016/j.ejmech.2018.10.028. Epub 2018 Oct 15.

DOI:10.1016/j.ejmech.2018.10.028
PMID:30342425
Abstract

Sirtuin (Yeast Silent Information RegulatorsⅡ, Sir2) was first discovered in the 1970s. Because of its function by removing acetylated groups from histones in the presence of nicotinamide adenine dinucleotide (NAD), waves of research have assessed the potential of Sirtuin as a therapeutic target. The Sirtuin family, which is widely distributed throughout the nature, has been divided into seven human isoforms (Sirt1-Sirt7). They are thought to be closely related to some aging diseases such as cardiovascular disorders, neurodegeneration, and tumors. Herein, we present a comprehensive review of the structure, function and modulators of Sirtuins, which is expected to be beneficial to relevant studies.

摘要

Sirtuin(酵母沉默信息调节因子Ⅱ,Sir2)于 20 世纪 70 年代首次被发现。由于其在烟酰胺腺嘌呤二核苷酸(NAD)存在的情况下从组蛋白上去除乙酰化基团的功能,一波又一波的研究评估了 Sirtuin 作为治疗靶点的潜力。Sirtuin 家族广泛存在于自然界中,已被分为七种人类同工酶(Sirt1-Sirt7)。它们被认为与一些衰老疾病密切相关,如心血管疾病、神经退行性疾病和肿瘤。在此,我们对 Sirtuins 的结构、功能和调节剂进行了全面综述,以期对相关研究有所裨益。

相似文献

1
An overview of Sirtuins as potential therapeutic target: Structure, function and modulators.Sirtuins 作为潜在治疗靶点的概述:结构、功能和调节剂。
Eur J Med Chem. 2019 Jan 1;161:48-77. doi: 10.1016/j.ejmech.2018.10.028. Epub 2018 Oct 15.
2
Biology, Chemistry, and Pharmacology of Sirtuins.沉默调节蛋白的生物学、化学及药理学
Methods Enzymol. 2016;574:183-211. doi: 10.1016/bs.mie.2016.03.011. Epub 2016 Mar 28.
3
Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).作为NAD+依赖的组蛋白去乙酰化酶(沉默调节蛋白)抑制剂的苏拉明类似物的构效关系研究
ChemMedChem. 2007 Oct;2(10):1419-31. doi: 10.1002/cmdc.200700003.
4
Inhibitors of NAD+ dependent histone deacetylases (sirtuins).NAD⁺依赖性组蛋白去乙酰化酶(沉默调节蛋白)抑制剂。
Curr Pharm Des. 2008;14(6):562-73. doi: 10.2174/138161208783885380.
5
Anticancer agents targeted to sirtuins.靶向 Sirtuins 的抗癌药物。
Molecules. 2014 Dec 4;19(12):20295-313. doi: 10.3390/molecules191220295.
6
The mimics of N-acyl-lysine derived from cysteine as sirtuin inhibitors.源自半胱氨酸的N-酰基赖氨酸类似物作为沉默调节蛋白抑制剂。
Bioorg Med Chem Lett. 2018 Aug 1;28(14):2375-2378. doi: 10.1016/j.bmcl.2018.06.030. Epub 2018 Jun 18.
7
Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential.Sirtuin 抑制:策略、抑制剂和治疗潜力。
Trends Pharmacol Sci. 2017 May;38(5):459-472. doi: 10.1016/j.tips.2017.01.009. Epub 2017 Apr 5.
8
Differential modulation of SIRT6 deacetylase and deacylase activities by lysine-based small molecules.基于赖氨酸的小分子对SIRT6脱乙酰酶和去酰基酶活性的差异调节
Mol Divers. 2020 Aug;24(3):655-671. doi: 10.1007/s11030-019-09971-2. Epub 2019 Jun 25.
9
Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications.人源 sirtuin 同工酶的特性分析进展:化学性质、靶标和治疗应用。
Curr Med Chem. 2011;18(13):1919-35. doi: 10.2174/092986711795590084.
10
Emerging Therapeutic Potential of SIRT6 Modulators.SIRT6 调节剂的新兴治疗潜力。
J Med Chem. 2021 Jul 22;64(14):9732-9758. doi: 10.1021/acs.jmedchem.1c00601. Epub 2021 Jul 2.

引用本文的文献

1
Sirtuins as mediators and targets of arsenic toxicity: unraveling signaling pathway crosstalk.沉默调节蛋白作为砷毒性的介质和靶点:揭示信号通路间的相互作用
Arch Toxicol. 2025 Aug 22. doi: 10.1007/s00204-025-04158-1.
2
Posttranslational Modification in Bone Homeostasis and Osteoporosis.骨稳态与骨质疏松中的翻译后修饰
MedComm (2020). 2025 Apr 1;6(4):e70159. doi: 10.1002/mco2.70159. eCollection 2025 Apr.
3
Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article.作为表观遗传靶点抑制剂的抗癌苯并咪唑衍生物:一篇综述文章。
RSC Adv. 2025 Jan 13;15(2):966-1010. doi: 10.1039/d4ra05014b. eCollection 2025 Jan 9.
4
Subcellular NAD pools are interconnected and buffered by mitochondrial NAD.亚细胞NAD池相互连接,并由线粒体NAD缓冲。
Nat Metab. 2024 Dec;6(12):2319-2337. doi: 10.1038/s42255-024-01174-w. Epub 2024 Dec 13.
5
Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.靶向沉默调节蛋白治疗癌症:表观遗传学修饰及其他。
Theranostics. 2024 Oct 14;14(17):6726-6767. doi: 10.7150/thno.100667. eCollection 2024.
6
Gut aging: A wane from the normal to repercussion and gerotherapeutic strategies.肠道衰老:从正常状态衰退至产生不良影响及老年治疗策略
Heliyon. 2024 Sep 12;10(19):e37883. doi: 10.1016/j.heliyon.2024.e37883. eCollection 2024 Oct 15.
7
Sirtuin Expression in Insulin-Sensitive Tissues of Rats with Impaired Glucose Tolerance is not Affected by Resistance Training or Zinc Supplementation.糖耐量受损大鼠胰岛素敏感组织中的沉默调节蛋白表达不受抗阻训练或补锌的影响。
Biol Trace Elem Res. 2024 Oct 1. doi: 10.1007/s12011-024-04397-w.
8
Symmetrical 2,7-disubstituted 9H-fluoren-9-one as a novel and promising scaffold for selective targeting of SIRT2.对称的2,7-二取代9H-芴-9-酮作为一种新型且有前景的选择性靶向SIRT2的骨架。
Arch Pharm (Weinheim). 2024 Dec;357(12):e2400661. doi: 10.1002/ardp.202400661. Epub 2024 Sep 28.
9
Activation and inhibition of sirtuins: From bench to bedside.沉默调节蛋白的激活与抑制:从实验室到临床应用
Med Res Rev. 2025 Mar;45(2):484-560. doi: 10.1002/med.22076. Epub 2024 Aug 31.
10
A High-Fat and High-Fructose Diet Exacerbates Liver Dysfunction by Regulating Sirtuins in a Murine Model.在小鼠模型中,高脂高果糖饮食通过调节沉默信息调节因子加剧肝功能障碍。
Life (Basel). 2024 Jun 5;14(6):729. doi: 10.3390/life14060729.